Tags

Type your tag names separated by a space and hit enter

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
Pharmacotherapy 2007; 27(5):715-28P

Abstract

A prescription form of omega-3 fatty acids has been approved by the United States Food and Drug Administration as an adjunct to diet for the treatment of very high triglyceride levels. The active ingredients of omega-3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are responsible for the triglyceride lowering. The prescription product contains a total of 0.84 g of these two active ingredients in every 1-g capsule of omega-3 fatty acids. The total EPA and DHA dose recommended for triglyceride lowering is approximately 2-4 g/day. Fish oil products containing EPA and DHA are available without a prescription, but the American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care. In patients with triglyceride levels above 500 mg/dl, approximately 4 g/day of EPA and DHA reduces triglyceride levels 45% and very low-density lipoprotein cholesterol levels by more than 50%. Low-density lipoprotein cholesterol levels may increase depending on the baseline triglyceride level, but the net effect of EPA and DHA therapy is a reduction in non-high-density lipoprotein cholesterol level. Alternatively, patients may receive one of the fibrates (gemfibrozil or fenofibrate) or niacin for triglyceride lowering if their triglyceride levels are higher than 500 mg/dl. In controlled trials, prescription omega-3 fatty acids were well tolerated, with a low rate of both adverse events and treatment-associated discontinuations. The availability of prescription omega-3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia.

Authors+Show Affiliations

School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA. jmckenney@ncrinc.netNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17461707

Citation

McKenney, James M., and Domenic Sica. "Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia." Pharmacotherapy, vol. 27, no. 5, 2007, pp. 715-28.
McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27(5):715-28.
McKenney, J. M., & Sica, D. (2007). Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy, 27(5), pp. 715-28.
McKenney JM, Sica D. Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia. Pharmacotherapy. 2007;27(5):715-28. PubMed PMID: 17461707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. AU - McKenney,James M, AU - Sica,Domenic, PY - 2007/4/28/pubmed PY - 2007/6/27/medline PY - 2007/4/28/entrez SP - 715 EP - 28 JF - Pharmacotherapy JO - Pharmacotherapy VL - 27 IS - 5 N2 - A prescription form of omega-3 fatty acids has been approved by the United States Food and Drug Administration as an adjunct to diet for the treatment of very high triglyceride levels. The active ingredients of omega-3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are responsible for the triglyceride lowering. The prescription product contains a total of 0.84 g of these two active ingredients in every 1-g capsule of omega-3 fatty acids. The total EPA and DHA dose recommended for triglyceride lowering is approximately 2-4 g/day. Fish oil products containing EPA and DHA are available without a prescription, but the American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care. In patients with triglyceride levels above 500 mg/dl, approximately 4 g/day of EPA and DHA reduces triglyceride levels 45% and very low-density lipoprotein cholesterol levels by more than 50%. Low-density lipoprotein cholesterol levels may increase depending on the baseline triglyceride level, but the net effect of EPA and DHA therapy is a reduction in non-high-density lipoprotein cholesterol level. Alternatively, patients may receive one of the fibrates (gemfibrozil or fenofibrate) or niacin for triglyceride lowering if their triglyceride levels are higher than 500 mg/dl. In controlled trials, prescription omega-3 fatty acids were well tolerated, with a low rate of both adverse events and treatment-associated discontinuations. The availability of prescription omega-3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/17461707/Role_of_prescription_omega_3_fatty_acids_in_the_treatment_of_hypertriglyceridemia_ L2 - https://doi.org/10.1592/phco.27.5.715 DB - PRIME DP - Unbound Medicine ER -